Compton Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-14,199
| Closed | -$984K | – | 15 |
|
|
2023
Q1 | $984K | Sell |
14,199
-16,885
| -54% | -$1.19M | 2.12% | 10 |
|
|
2022
Q4 | $2.24M | Sell |
31,084
-4,820
| -13% | -$363K | 1.61% | 20 |
|
|
2022
Q3 | $2.55M | Sell |
35,904
-2,012
| -5% | -$146K | 1.71% | 17 |
|
|
2022
Q2 | $2.92M | Sell |
37,916
-22,065
| -37% | -$1.68M | 1.61% | 16 |
|
|
2022
Q1 | $4.38M | Sell |
59,981
-1,300
| -2% | -$87.3K | 1.22% | 18 |
|
|
2021
Q4 | $3.82M | Sell |
61,281
-400
| -0.6% | -$23.5K | 0.99% | 22 |
|
|
2021
Q3 | $3.65M | Sell |
61,681
-350
| -0.6% | -$23.1K | 1.07% | 22 |
|
|
2021
Q2 | $4.14M | Sell |
62,031
-1,100
| -2% | -$71.7K | 1.22% | 17 |
|
|
2021
Q1 | $3.98M | Sell |
63,131
-600
| -0.9% | -$37.3K | 1.25% | 20 |
|
|
2020
Q4 | $3.95M | Sell |
63,731
-400
| -0.6% | -$24.6K | 1.34% | 18 |
|
|
2020
Q3 | $3.87M | Sell |
64,131
-1,098
| -2% | -$66.1K | 1.48% | 17 |
|
|
2020
Q2 | $3.83M | Buy |
65,229
+490
| +0.8% | +$29.3K | 1.61% | 14 |
|
|
2020
Q1 | $3.61M | Sell |
64,739
-1,070
| -2% | -$65.4K | 1.78% | 12 |
|
|
2019
Q4 | $4.22M | Buy |
65,809
+29,890
| +83% | +$1.71M | 1.64% | 15 |
|
|
2019
Q3 | $1.82M | Sell |
35,919
-150
| -0.4% | -$7.05K | 0.76% | 47 |
|
|
2019
Q2 | $1.64M | Buy |
36,069
+600
| +2% | +$27.9K | 0.69% | 49 |
|
|
2019
Q1 | $1.69M | Sell |
35,469
-120
| -0.3% | -$5.98K | 0.74% | 46 |
|
|
2018
Q4 | $1.85M | Sell |
35,589
-1,550
| -4% | -$83.3K | 0.88% | 41 |
|
|
2018
Q3 | $2.31M | Hold |
37,139
| – | – | 0.91% | 37 |
|
|
2018
Q2 | $2.06M | Buy |
37,139
+147
| +0.4% | +$7.94K | 0.87% | 39 |
|
|
2018
Q1 | $2.34M | Sell |
36,992
-1,225
| -3% | -$78.8K | 0.99% | 33 |
|
|
2017
Q4 | $2.34M | Buy |
38,217
+205
| +0.5% | +$12.8K | 1% | 31 |
|
|
2017
Q3 | $2.42M | Buy |
38,012
+1,300
| +4% | +$75.9K | 1.09% | 27 |
|
|
2017
Q2 | $2.05M | Sell |
36,712
-100
| -0.3% | -$5.44K | 0.93% | 35 |
|
|
2017
Q1 | $2M | Buy |
36,812
+4,168
| +13% | +$229K | 0.98% | 33 |
|
|
2016
Q4 | $1.91M | Sell |
32,644
-32,094
| -50% | -$1.75M | 1% | 31 |
|
|
2016
Q3 | $4.12M | Buy |
64,738
+32,644
| +102% | +$2.1M | 1.14% | 28 |
|
|
2016
Q2 | $2.36M | Sell |
32,094
-910
| -3% | -$64.3K | 1.32% | 22 |
|
|
2016
Q1 | $2.11M | Buy |
33,004
+40
| +0.1% | +$2.52K | 1.18% | 25 |
|
|
2015
Q4 | $2.27M | Sell |
32,964
-300
| -0.9% | -$19.8K | 1.28% | 21 |
|
|
2015
Q3 | $1.97M | Buy |
33,264
+80
| +0.2% | +$5.08K | 0.71% | 24 |
|
|
2015
Q2 | $2.21M | Sell |
33,184
-150
| -0.4% | -$9.88K | 1.21% | 25 |
|
|
2015
Q1 | $2.15M | Sell |
33,334
-500
| -1% | -$31.3K | 1.2% | 25 |
|
|
2014
Q4 | $2M | Sell |
33,834
-300
| -0.9% | -$16.9K | 1.09% | 28 |
|
|
2014
Q3 | $1.75M | Sell |
34,134
-550
| -2% | -$27.5K | 0.95% | 30 |
|
|
2014
Q2 | $1.68M | Sell |
34,684
-550
| -2% | -$27.1K | 0.91% | 32 |
|
|
2014
Q1 | $1.83M | Sell |
35,234
-200
| -0.6% | -$10.6K | 1.06% | 28 |
|
|
2013
Q4 | $1.88M | Hold |
35,434
| – | – | 1.07% | 30 |
|
|
2013
Q3 | $1.64M | Buy |
35,434
+300
| +0.9% | +$13.2K | 1% | 32 |
|
|
2013
Q2 | $1.57M | Buy |
+35,134
| New | +$1.53M | 0.97% | 32 |
|
Other funds holding BMY
Compton Capital Management's BMY Position: Q2 2023 in Review
Compton Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 14,199 shares — an estimated $984K sold.
Compton Capital Management first reported a position in BMY in Q2 2013 and held it in 40 quarters. The position peaked at $4.38M in Q1 2022. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.
- Compton Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
- Compton Capital Management sold 14,199 Bristol-Myers Squibb shares in Q2 2023, an estimated $984K.
- Compton Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 40 quarters.
- Compton Capital Management's Bristol-Myers Squibb position peaked at $4.38M in Q1 2022.
- 2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.
Based on Compton Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.